Topical imiquimod 5% cream therapy versus photodynamic therapy with methyl-aminolaevulinate 16% cream of actinic keratoses in organ transplant recipients - imiquimod vs pdt of ak in otr

Medizinische Universität Wien, Univ. Klinik f. Dermatologie0 个研究点开始时间: 2011年11月17日最近更新: 2015年8月4日

适应症

试验速览

暂无简介。

•Age 18 years or older
•Patients who had received a kidney, liver, lung or heart transplant more than 3 years prior to inclusion into the study
•Patients who had been treated at least 6 month prior to study entry with a stable twofold or threefold immunsupressive treatment
•Patients who had clinically confirmed epithelial dysplasia (actinic keratoses) in at least two anatomically separated contralateral areas on the face and/or scalp with comparable size and extension and minimum distance of 5 cm
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 30

•Invasive squamous cell carcinoma or basal cell carcinoma in the treatment area
•Known allergy to imiquimod and aminolaevulinic acid
•Patients who have received retinoids, interferons or investigational drugs within 4 weeks of study initiation
•Patients who are participating in other dermatological study
•Patients with instable organ function
•Persistent Hepatitis B or C infections
•Any evidence of systemic cancer
•Patients who have received any systemic cancer chemotherapy or radiation therapy
•Pregnant and lactating women

发起方

Medizinische Universität Wien, Univ. Klinik f. Dermatologie